PACB News and Press, Pacific Biosciences of California Inc. From 05/20/22

Gainers: O2Micro International Limited (OIIM) +20%. Fluence Energy (FLNC) +7%. Allarity Therapeutics (ALLR) +7%. SIGA Technologies (SIGA) +6%. Blackbaud (BLKB) +5%. Losers: Redbox Entertainment  (RDBX) -10%. Pacific Biosciences of California (PACB) -6%. Jamf Holding  (JAMF...

MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time ...

Pacific Biosciences of California (NASDAQ:PACB) stock fell May 5 after  Cantor Fitzgerald cut its price target on the life sciences company to $19 from $23, following Q1 results. Cantor Fitzgerald analyst Ross Osborn kept an Overweight rating on the shares. Q1 revenues grew ~14...

Pacific Biosciences of California, Inc. (PACB) Q1 2022 Earnings Conference Call May 4, 2022, 17:00 PM ET Company Participants Todd Friedman - Director, IR Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Dan Brennan - Cow...

Although PacBio's (NASDAQ:PACB) Q1 2022 net loss narrowed 7% to $81.5M (-$0.37 basic and diluted per share), the biotech still missed consensus estimates on the bottom line. Revenue of ~$33.2M in the quarter was ~14.4% year-over-year increase. PacBio (PACB) was negatively impacted in the...

Pacific Biosciences of California press release (NASDAQ:PACB): Q1 GAAP EPS of -$0.37 misses by $0.05. Revenue of $33.17M (+14.4% Y/Y) beats by $0.35M. For further details see: Pacific Biosciences of California GAAP EPS of -$0.37 misses by $0.05, revenue of $33.17M beats by $0.35M

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period. Deliver...

Corteva (NYSE:CTVA) is scheduled to announce Q1 results on Wednesday, May 4, after market close. Consensus EPS estimate is $0.81 (+2.5% Y/Y) and consensus revenue estimate is $4.47B (+6.4% Y/Y). Over the last 2 years, CTVA has beaten EPS estimates 88% of the time and reven...

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediat...

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems . ...